Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Infectious Disease
•
Vaccines
•
General Infectious Disease
Under what circumstances would you recommend the maternal RSV vaccine for a pregnant patient if nirsevimab will also be available for the infant after birth?
Related Questions
What is your approach to a patient with undetectable MMR titers checked prior to or during immunosuppression and a history of MMR vaccination in childhood?
Would you consider stepping down from an echinocandin to azole therapy prior to the end of an initial six-week course for fluconazole-susceptible Candida albicans endocarditis in the absence of valve surgery?
Is there a role for beta-lactams as step-down oral therapy for uncomplicated gram-negative bacteremia?
How do you approach treatment of tuberculous scleritis in pregnancy?
Do you routinely transition from inpatient vancomycin to outpatient daptomycin to decrease the risk of nephrotoxicity and reduce the burden of lab monitoring in a patient with MRSA infection being discharged on home IV antibiotics?
Do you use oral fosfomycin as a treatment option for uncomplicated cystitis due to ESBL producing E coli?
Have you incorporated the use of steroids for patients with severe community-acquired pneumonia?
Do you treat Stenotrophomonas maltophilia bacteremia with combination therapy and if so, what is your preferred combination of antibacterials?
What is your approach to RSV vaccination in immunocompromised patients?
What is your approach to recurrent asymptomatic bacteriuria in pregnancy for patients without personal history of recurrent UTIs or pyelonephritis?
